10Y annualized return is
positive but below market average
at 7.2% per year
TECH has met or exceeded earnings expectations in
few
recent quarters (3/10)
Strong Market Growth Potential
Strong Gross and Operating Margins
Strong Liquidity Position
Low Debt Levels
📈 Strong Revenue Growth
🔬 Diverse Product Portfolio
💡 Innovation in AI and Protein Engineering
🚀 Optimistic Growth Outlook
🔍 Expansion in Precision Diagnostics
High Valuation Ratios
Moderate Return on Equity
Moderate Interest Coverage
📉 Challenges in China
⚠️ Market Volatility Risks
Overall, Bio-Techne demonstrates strong business quality with robust revenue growth and a diverse product portfolio, complemented by innovative capabilities in AI and protein engineering. Future prospects appear positive, driven by anticipated growth in core markets, although challenges in specific regions and market volatility must be monitored.
Analysis Date: February 5, 2025
Last Updated: March 12, 2025
Past performance does not guarantee future results. The data presented is indicative and may not be updated in real-time.
Bio-Techne Corporation is a company that makes tools and products used in scientific research and medical testing. They provide important materials, like proteins and tests, that help scientists study diseases and develop new medicines. Their products are used in labs around the world to help with diagnosing and understanding health issues. In simple terms, Bio-Techne helps researchers and doctors get the information they need to improve health and medicine.
Streams of revenue
Geographic Distribution
Core Products
Business Type
Business to Business
Competitive Advantages
Key Business Risks
Latest News
Partnership Extends Cycurion's Sales Presence Into 135 Countries via LSV's Strategic Partnership with Nokia Partnership Extends Cycurion's Sales Prese...
Antwerp, April 22, 2025 (GLOBE NEWSWIRE) -- CMB.TECH NV (NYSE: CMBT & Euronext: CMBT) (“CMB.TECH” or the “Company”) invites its shareholders to partic...
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Benjamin Graham's value investing approach focuses on finding stocks with a significant margin of safety between their intrinsic value and market price.
Intrinsic Value
Estimated fair value based on Graham's formula
$12.48
Current Market Price: $51.61
IV/P Ratio: 0.24x (>1.0 indicates undervalued)
Margin of Safety
Gap between intrinsic value and market price
-314.0%
Graham recommended a minimum of 20-30% margin of safety
Higher values indicate a greater potential discount to fair value
Graham Criteria Checklist
Benjamin Graham's value investing checklist for TECH
Positive earnings (5+ years)
Dividend history (5+ years)
P/E ratio ≤ 20 (51.82)
P/B ratio ≤ 1.5 (3.92)
Current ratio ≥ 2.0 (3.94x)
Long-term debt < Net current assets (0.81x)
Margin of safety (-314.0%)
TECH does not meet all Graham criteria
Trailing Twelve Months (TTM) values provide a view of the company's performance over the last year.
Profitability metrics measure a company's ability to generate earnings relative to its revenue, operating costs, and other relevant metrics. Higher values generally indicate better performance.
Return on Equity (ROE)
Measures how efficiently a company uses its equity to generate profits
7.61%
Higher values indicate better returns for shareholders
TTM (as of 2025-04-30)
Gross Profit Margin
Percentage of revenue retained after accounting for cost of goods sold
65.80%
Higher values indicate better efficiency in production
TTM (as of 2025-04-30)
Net Profit Margin
Percentage of revenue retained after accounting for all expenses
13.22%
Higher values indicate better overall profitability
TTM (as of 2025-04-30)
The gross profit margin of 65.80% and operating profit margin of 19.93% indicate effective cost management and a strong ability to convert sales into profit.
The return on equity (ROE) of 7.61% is relatively low, suggesting that the company may not be utilizing shareholder equity as effectively as it could be.
Financial health metrics assess a company's ability to meet its financial obligations and its overall financial stability.
Debt to Equity Ratio
Total debt divided by total equity
0.19x
Lower values indicate less financial leverage and risk
Less than 1.0 is conservative, 1.0-2.0 is moderate, >2.0 indicates high risk
Q2 2025
Current Ratio
Current assets divided by current liabilities
3.94x
Higher values indicate better short-term liquidity
Less than 1.0 is concerning, 1.0-2.0 is adequate, greater than 2.0 is good
Q2 2025
The current ratio of 3.94 and quick ratio of 2.77 indicate a solid liquidity position, showing that the company can easily meet its short-term obligations.
With a debt-to-equity ratio of 0.19, the company has a conservative capital structure, suggesting lower financial risk.
Although the interest coverage ratio is healthy at 21.99, it indicates that while the company can meet its interest obligations, it may not have as much room for error compared to higher ratios.
Meeting Expectations
Higher values indicate better execution and credibility
Recent Results
EPS
Bio-Techne reported a 9% organic revenue growth in Q2, driven by the improving biopharma end markets and strong performance in their GMP protein analytical instrumentation and Exosome VX franchises.
The company has a robust portfolio addressing critical needs in biopharma, including cell and gene therapy, precision diagnostics, and protein analysis, which positions them well in high growth markets.
Bio-Techne is leveraging AI for developing designer proteins, which enhances their competitive edge by offering products with superior functionalities.
Sales in China declined low single digits due to a challenging economic environment, although recovery is expected in the coming quarters.
Management expects organic revenue growth to continue with an anticipated return to modest positive growth in China and strong demand from large pharma customers.
The launch of new precision diagnostic tools and the growing adoption of existing ones indicate strong potential for revenue growth in this segment.
The company acknowledges potential headwinds from foreign exchange fluctuations and uncertainties in government funding in the academic sector.